PURPOSE: Determine the effect of minute quantities of sub-visible aggregates on the in vitro immunogenicity of clinically relevant protein therapeutics. METHODS: Monoclonal chimeric (rituximab) and humanized (trastuzumab) antibodies were subjected to fine-tuned stress conditions to achieve low levels (<3% of total protein) of sub-visible aggregates. The effect of stimulating human dendritic cells (DC) and CD4(+) T cells with the aggregates was measured in vitro using cytokine secretion, proliferation and confocal microscopy. RESULTS: Due to its intrinsic high clinical immunogenicity, aggregation of rituximab had minimal effects on DC activation and T cell responses compared to monomeric rituximab. However, in the case of trastuzumab (low clinical immunogenicity) small quantities of aggregates led to potent CD4(+) T cell proliferation as a result of strong cytokine and co-stimulatory signals derived from DC. Consistent with this, confocal studies showed that stir-stressed rituximab was rapidly internalised and associated with late endosomes of DC. CONCLUSIONS: These data link minute amounts of aggregates with activation of the innate immune response, involving DC, resulting in T cell activation. Thus, when protein therapeutics with little or no clinical immunogenicity, such as trastuzumab, contain minute amounts of sub-visible aggregates, they are associated with significantly increased potential risk of clinical immunogenicity.
PURPOSE: Determine the effect of minute quantities of sub-visible aggregates on the in vitro immunogenicity of clinically relevant protein therapeutics. METHODS: Monoclonal chimeric (rituximab) and humanized (trastuzumab) antibodies were subjected to fine-tuned stress conditions to achieve low levels (<3% of total protein) of sub-visible aggregates. The effect of stimulating human dendritic cells (DC) and CD4(+) T cells with the aggregates was measured in vitro using cytokine secretion, proliferation and confocal microscopy. RESULTS: Due to its intrinsic high clinical immunogenicity, aggregation of rituximab had minimal effects on DC activation and T cell responses compared to monomeric rituximab. However, in the case of trastuzumab (low clinical immunogenicity) small quantities of aggregates led to potent CD4(+) T cell proliferation as a result of strong cytokine and co-stimulatory signals derived from DC. Consistent with this, confocal studies showed that stir-stressed rituximab was rapidly internalised and associated with late endosomes of DC. CONCLUSIONS: These data link minute amounts of aggregates with activation of the innate immune response, involving DC, resulting in T cell activation. Thus, when protein therapeutics with little or no clinical immunogenicity, such as trastuzumab, contain minute amounts of sub-visible aggregates, they are associated with significantly increased potential risk of clinical immunogenicity.
Authors: A Vecchi; L Massimiliano; S Ramponi; W Luini; S Bernasconi; R Bonecchi; P Allavena; M Parmentier; A Mantovani; S Sozzani Journal: J Leukoc Biol Date: 1999-09 Impact factor: 4.962
Authors: B Mianowska; A Szadkowska; I Pietrzak; A Zmysłowska; O Wegner; J Tomczonek; J Bodalski; W Młynarski Journal: Pediatr Diabetes Date: 2011-03 Impact factor: 4.866
Authors: Christophe Dercamp; Karine Chemin; Christophe Caux; Giorgio Trinchieri; Alain P Vicari Journal: Cancer Res Date: 2005-09-15 Impact factor: 12.701
Authors: T Fehr; M F Bachmann; E Bucher; U Kalinke; F E Di Padova; A B Lang; H Hengartner; R M Zinkernagel Journal: J Exp Med Date: 1997-05-19 Impact factor: 14.307
Authors: Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa Journal: J Biol Chem Date: 2012-05-14 Impact factor: 5.157
Authors: Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay Journal: Proc Natl Acad Sci U S A Date: 2015-11-30 Impact factor: 11.205
Authors: Karthik Pisupati; Alexander Benet; Yuwei Tian; Solomon Okbazghi; Jukyung Kang; Michael Ford; Sergei Saveliev; K Ilker Sen; Eric Carlson; Thomas J Tolbert; Brandon T Ruotolo; Steven P Schwendeman; Anna Schwendeman Journal: MAbs Date: 2017-08-08 Impact factor: 5.857
Authors: Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso Journal: Semin Immunol Date: 2017-10-09 Impact factor: 11.130
Authors: Tina Rubic-Schneider; Masataka Kuwana; Brigitte Christen; Manuela Aßenmacher; Otmar Hainzl; Frank Zimmermann; Robert Fischer; Vera Koppenburg; Salah-Dine Chibout; Timothy M Wright; Andreas Seidl; Michael Kammüller Journal: Blood Adv Date: 2017-02-09